Siegfried Holding AG
SIX:SFZN

Watchlist Manager
Siegfried Holding AG Logo
Siegfried Holding AG
SIX:SFZN
Watchlist
Price: 1 114 CHF 0.91% Market Closed
Market Cap: 4.8B CHF
Have any thoughts about
Siegfried Holding AG?
Write Note

Siegfried Holding AG
Retained Earnings

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Siegfried Holding AG
Retained Earnings Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Retained Earnings CAGR 3Y CAGR 5Y CAGR 10Y
Siegfried Holding AG
SIX:SFZN
Retained Earnings
CHf1.2B
CAGR 3-Years
24%
CAGR 5-Years
21%
CAGR 10-Years
N/A
Bachem Holding AG
SIX:BANB
Retained Earnings
CHf717.9m
CAGR 3-Years
14%
CAGR 5-Years
14%
CAGR 10-Years
8%
Lonza Group AG
SIX:LONN
Retained Earnings
CHf9.5B
CAGR 3-Years
21%
CAGR 5-Years
22%
CAGR 10-Years
15%
Tecan Group AG
SIX:TECN
Retained Earnings
CHf1.5B
CAGR 3-Years
20%
CAGR 5-Years
18%
CAGR 10-Years
N/A
PolyPeptide Group AG
SIX:PPGN
Retained Earnings
€166.4m
CAGR 3-Years
4%
CAGR 5-Years
11%
CAGR 10-Years
N/A
SKAN Group AG
SIX:SKAN
Retained Earnings
CHf169m
CAGR 3-Years
64%
CAGR 5-Years
14%
CAGR 10-Years
N/A
No Stocks Found

Siegfried Holding AG
Glance View

Market Cap
4.8B CHF
Industry
Life Sciences Tools & Services

Siegfried Holding AG engages in the development and manufacture of active pharmaceutical ingredients for pharmaceutical clients with research and development programs, related intermediates, and controlled substances. The company is headquartered in Zofingen, Aargau and currently employs 3,432 full-time employees. The firm produces both drug substances and drug products. The drug substance portfolio includes contract development and manufacturing of both active pharmaceutical ingredients (APIs) and intermediates. The drug products portfolio comprises licensing and contract or co-development and manufacturing of oral solids and steriles. The firm's products and substances are developed for treatment of hypertension, benign prostate hyperplasia, depression, chronic myeloid leukemia, glaucoma, asthma, schizophrenia and bipolar disorders and diabetes. The firm operates production facilities in Switzerland, Germany, France, Malta, the United States and China.

SFZN Intrinsic Value
1 192.72 CHF
Undervaluation 7%
Intrinsic Value
Price

See Also

What is Siegfried Holding AG's Retained Earnings?
Retained Earnings
1.2B CHF

Based on the financial report for Jun 30, 2024, Siegfried Holding AG's Retained Earnings amounts to 1.2B CHF.

What is Siegfried Holding AG's Retained Earnings growth rate?
Retained Earnings CAGR 5Y
21%

Over the last year, the Retained Earnings growth was 59%. The average annual Retained Earnings growth rates for Siegfried Holding AG have been 24% over the past three years , 21% over the past five years .

Back to Top